Index - P/E - EPS (ttm) -1.37 Insider Own 59.93% Shs Outstand 17.42M Perf Week 3.27%
Market Cap 127.42M Forward P/E - EPS next Y -1.24 Insider Trans 0.10% Shs Float 7.36M Perf Month 6.77%
Income -22.38M PEG - EPS next Q -0.26 Inst Own 8.60% Short Float 12.01% Perf Quarter 6.61%
Sales 0.00M P/S - EPS this Y 20.28% Inst Trans 28.38% Short Ratio 9.01 Perf Half Y -10.22%
Book/sh 0.76 P/B 9.09 EPS next Y -8.33% ROA -124.61% Short Interest 0.88M Perf Year -49.93%
Cash/sh 1.06 P/C 6.55 EPS next 5Y - ROE -170.23% 52W Range 5.85 - 15.50 Perf YTD -16.79%
Dividend Est. - P/FCF - EPS past 5Y - ROI -159.62% 52W High -55.23% Beta 0.44
Dividend TTM - Quick Ratio 3.46 Sales past 5Y 0.00% Gross Margin - 52W Low 18.63% ATR (14) 0.42
Dividend Ex-Date - Current Ratio 3.46 EPS Y/Y TTM 4.05% Oper. Margin 0.00% RSI (14) 55.97 Volatility 5.36% 6.45%
Employees 13 Debt/Eq 0.00 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 20.50
Option/Short No / Yes LT Debt/Eq 0.00 EPS Q/Q 8.40% Payout - Rel Volume 0.20 Prev Close 6.62
Sales Surprise - EPS Surprise 36.98% Sales Q/Q - Earnings May 07 BMO Avg Volume 98.16K Price 6.94
SMA20 6.65% SMA50 5.98% SMA200 -11.60% Trades
Volume 20,102 Change 4.83%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-13-22 Initiated Ladenburg Thalmann
Buy
$21
May-28-24 06:10AM
May-24-24 09:55AM
May-16-24 08:30AM
May-07-24 09:06PM
01:53PM
08:00AM
Loading…
08:00AM
Apr-08-24 08:30AM
Apr-02-24 04:30PM
Mar-19-24 08:00AM
Mar-15-24 08:00AM
Mar-14-24 09:00AM
Mar-05-24 11:52PM
08:31AM
08:00AM
Feb-09-24 08:32AM
08:00AM
Loading…
08:00AM
Jan-03-24 08:00AM
Dec-18-23 08:00AM
Nov-08-23 08:00AM
Oct-24-23 08:00AM
Oct-16-23 09:35AM
Sep-25-23 07:30PM
Sep-21-23 08:00AM
Sep-12-23 08:00AM
Sep-06-23 08:00AM
Sep-01-23 08:00AM
Aug-17-23 08:00AM
Aug-11-23 07:01AM
Aug-10-23 06:24AM
Aug-09-23 08:00AM
06:26AM
Loading…
06:26AM
Aug-08-23 06:28AM
Aug-07-23 06:35AM
Aug-04-23 07:14AM
Aug-03-23 07:15AM
Aug-02-23 07:52AM
Aug-01-23 06:51AM
06:51AM
Jul-31-23 06:44AM
Jul-28-23 07:58AM
07:58AM
Jul-27-23 07:10AM
Jul-26-23 01:12PM
Jul-25-23 07:16AM
07:16AM
Jul-24-23 07:12AM
Jul-21-23 07:23AM
07:23AM
Jul-20-23 06:55AM
06:55AM
Jul-19-23 07:10AM
07:10AM
Jul-18-23 06:53AM
Jul-17-23 07:10AM
Jul-14-23 06:50AM
06:50AM
Jul-13-23 07:02AM
07:02AM
Jul-12-23 07:22AM
Jul-11-23 06:08AM
06:08AM
Jul-10-23 06:56AM
06:56AM
Jul-05-23 06:46AM
Jul-03-23 06:50AM
Jun-30-23 06:52AM
Jun-29-23 06:49AM
Jun-28-23 07:13AM
06:58AM
Jun-27-23 06:46AM
06:46AM
Jun-26-23 06:41AM
Jun-21-23 07:20AM
Jun-20-23 08:00AM
06:35AM
Jun-18-23 08:03AM
Jun-05-23 08:50AM
Jun-01-23 04:48AM
May-31-23 06:22AM
May-19-23 08:50AM
May-15-23 09:55AM
08:00AM
May-10-23 08:00AM
May-09-23 01:34PM
May-02-23 06:46AM
May-01-23 06:45AM
Apr-28-23 07:04AM
Apr-27-23 10:14AM
08:00AM
06:47AM
Apr-26-23 06:26AM
Apr-20-23 07:03AM
Apr-19-23 06:53AM
Apr-18-23 08:00AM
Apr-17-23 06:54AM
Apr-14-23 06:37AM
Apr-13-23 06:52AM
Apr-12-23 07:07AM
Apr-11-23 06:58AM
Apr-10-23 08:00AM
Nuvectis Pharma, Inc. is a preclinical stage biopharmaceutical company. It focuses on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its product pipeline includes NXP800 and NXP900. The company was founded by Ron Bentsur, Enrique Poradosu and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BENTSUR RON Chairman & CEO May 14 '24 Buy 6.74 1,940 13,076 3,246,424 May 15 09:16 AM BENTSUR RON Chairman & CEO May 10 '24 Buy 6.40 2,000 12,800 3,244,484 May 13 08:51 AM Shemesh Shay Chief Dev. & Ops. Officer May 10 '24 Buy 6.32 1,113 7,034 1,493,068 May 13 08:47 AM Poradosu Enrique Chief Science & Business Off May 10 '24 Buy 6.29 500 3,145 1,504,319 May 13 08:49 AM BENTSUR RON Chairman & CEO Mar 18 '24 Buy 10.29 5,000 51,450 3,242,484 Mar 19 08:00 AM BENTSUR RON Chairman & CEO Oct 10 '23 Buy 11.08 640 7,091 3,237,484 Oct 12 04:05 PM BENTSUR RON Chairman & CEO Oct 09 '23 Buy 11.19 830 9,288 3,236,844 Oct 10 08:30 AM BENTSUR RON Chairman & CEO Oct 06 '23 Buy 11.27 250 2,818 3,236,014 Oct 10 08:30 AM BENTSUR RON Chairman & CEO Oct 05 '23 Buy 11.09 1,400 15,526 3,235,764 Oct 06 08:37 AM BENTSUR RON Chairman & CEO Oct 04 '23 Buy 10.95 1,820 19,929 3,234,364 Oct 06 08:37 AM BENTSUR RON Chairman & CEO Aug 16 '23 Buy 15.15 115 1,742 3,232,544 Aug 16 04:05 PM BENTSUR RON Chairman & CEO Aug 15 '23 Buy 14.34 235 3,370 3,232,429 Aug 16 04:05 PM BENTSUR RON Chairman & CEO Aug 11 '23 Buy 14.66 180 2,639 3,232,194 Aug 11 06:07 PM BENTSUR RON Chairman & CEO Aug 08 '23 Buy 14.83 120 1,780 3,232,014 Aug 11 06:07 PM Mosseri Marlio Charles 10% Owner Jul 31 '23 Buy 13.88 860 11,937 2,595,000 Aug 01 08:00 AM Mosseri Marlio Charles 10% Owner Jul 28 '23 Buy 13.91 2,584 35,943 2,594,140 Jul 31 08:00 AM Mosseri Marlio Charles 10% Owner Jul 27 '23 Buy 13.98 1,556 21,753 2,591,556 Jul 28 08:00 AM
Index - P/E - EPS (ttm) -1.82 Insider Own 18.86% Shs Outstand 45.90M Perf Week 11.87%
Market Cap 29.15M Forward P/E - EPS next Y -0.88 Insider Trans 0.00% Shs Float 37.24M Perf Month 0.16%
Income -60.24M PEG - EPS next Q -0.34 Inst Own 36.61% Short Float 2.84% Perf Quarter -45.95%
Sales 1.16M P/S 25.13 EPS this Y 36.08% Inst Trans 10.31% Short Ratio 1.28 Perf Half Y -52.25%
Book/sh 0.55 P/B 1.16 EPS next Y 24.12% ROA -95.84% Short Interest 1.06M Perf Year -81.59%
Cash/sh 0.76 P/C 0.84 EPS next 5Y - ROE -191.36% 52W Range 0.53 - 3.90 Perf YTD -67.60%
Dividend Est. - P/FCF - EPS past 5Y -18.68% ROI -144.58% 52W High -83.72% Beta -0.12
Dividend TTM - Quick Ratio 3.61 Sales past 5Y -43.84% Gross Margin -223.68% 52W Low 20.74% ATR (14) 0.06
Dividend Ex-Date - Current Ratio 3.80 EPS Y/Y TTM 1.74% Oper. Margin -5436.24% RSI (14) 42.12 Volatility 7.61% 7.57%
Employees 107 Debt/Eq 0.71 Sales Y/Y TTM - Profit Margin -5197.76% Recom 1.50 Target Price 5.17
Option/Short Yes / Yes LT Debt/Eq 0.66 EPS Q/Q 45.56% Payout - Rel Volume 0.78 Prev Close 0.63
Sales Surprise -36.89% EPS Surprise 24.05% Sales Q/Q - Earnings Aug 06 AMC Avg Volume 824.51K Price 0.64
SMA20 9.52% SMA50 -33.21% SMA200 -58.35% Trades
Volume 639,810 Change 1.13%
Date
Action
Analyst
Rating Change
Price Target Change
Jun-25-24 Downgrade BTIG Research
Buy → Neutral
Jul-28-23 Initiated Piper Sandler
Overweight
$10
Jun-15-23 Initiated BTIG Research
Buy
$15
Apr-28-21 Initiated Truist
Buy
$12
Oct-22-19 Initiated Oppenheimer
Outperform
$9
Jul-23-24 04:05PM
Jul-16-24 04:05PM
Jul-10-24 09:55AM
Jun-26-24 08:01AM
Jun-25-24 10:31AM
08:28AM
Loading…
08:28AM
07:37AM
Jun-24-24 08:53PM
05:25PM
04:15PM
Jun-13-24 04:05PM
Jun-03-24 07:00AM
May-23-24 04:09PM
May-01-24 07:00AM
Mar-21-24 12:00PM
09:00AM
Loading…
Mar-20-24 09:00AM
Feb-13-24 08:51AM
Feb-12-24 04:05PM
Jan-18-24 08:00AM
Dec-27-23 07:30AM
Dec-21-23 01:40AM
Nov-15-23 04:05PM
(GlobeNewswire) +23.57%
-8.96%
Nov-14-23 10:00AM
Nov-13-23 04:05PM
Nov-03-23 12:00PM
Oct-19-23 04:05PM
Oct-17-23 04:05PM
(GlobeNewswire) +8.48%
-6.17%
07:30AM
Oct-16-23 07:30AM
07:00AM
07:30AM
Loading…
Oct-04-23 07:30AM
Oct-02-23 04:05PM
Sep-27-23 09:00AM
Sep-18-23 04:05PM
(GlobeNewswire) -7.95%
+6.83%
Sep-07-23 07:30AM
Sep-06-23 07:00AM
Aug-10-23 04:05PM
Aug-08-23 09:55AM
Aug-07-23 04:05PM
Aug-01-23 04:05PM
Jul-28-23 10:13AM
Jul-24-23 04:05PM
(GlobeNewswire) -6.11%
-5.42%
Jun-22-23 04:05PM
Jun-15-23 04:10PM
04:05PM
Jun-09-23 06:34AM
Jun-08-23 06:43AM
Jun-07-23 08:25AM
Jun-06-23 06:34AM
Jun-05-23 06:44AM
Jun-02-23 06:56AM
Jun-01-23 06:29AM
May-31-23 06:40AM
May-30-23 06:50AM
May-26-23 06:59AM
May-25-23 06:38AM
May-24-23 06:43AM
May-23-23 06:33AM
May-22-23 07:49AM
May-19-23 07:03AM
May-18-23 06:39AM
May-17-23 06:35AM
May-16-23 04:05PM
Apr-19-23 09:00AM
Mar-31-23 06:36AM
Mar-23-23 04:05PM
Mar-14-23 04:35PM
Mar-10-23 07:04AM
Feb-22-23 07:00AM
Feb-09-23 04:05PM
(GlobeNewswire) -6.21%
-7.83%
Jan-30-23 07:00AM
Jan-24-23 04:05PM
Jan-17-23 04:05PM
Dec-13-22 09:25AM
Nov-17-22 04:05PM
Nov-10-22 09:00AM
Nov-08-22 04:05PM
Oct-24-22 07:30AM
Oct-20-22 04:05PM
Oct-17-22 04:05PM
Oct-05-22 08:00AM
Oct-03-22 07:30AM
Sep-16-22 04:05PM
Aug-23-22 08:00AM
Aug-11-22 04:05PM
Jul-27-22 04:05PM
Jun-28-22 04:10PM
(GlobeNewswire) -7.81%
+8.13%
04:05PM
Jun-14-22 04:30PM
Jun-01-22 07:00AM
May-17-22 04:05PM
07:00AM
May-16-22 07:05AM
May-06-22 06:29AM
Apr-25-22 04:05PM
07:00AM
Apr-18-22 07:00AM
Apr-11-22 07:00AM
Mar-08-22 04:35PM
Feb-22-22 04:52AM
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company, which engages in the development of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. It operates through the Beyond Air and Beyond Cancer segments. The company was founded on April 28, 2015 and is headquartered in Garden City, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Avniel Amir Chief Business Officer Dec 28 '23 Sale 2.05 13,733 28,217 0 Dec 29 04:23 PM Avniel Amir Chief Business Officer Dec 28 '23 Sale 2.06 11,267 23,234 685,760 Dec 29 04:23 PM Myers Jeff Lynn Chief Medical Officer Dec 27 '23 Sale 2.21 3,423 7,579 46,577 Dec 29 04:15 PM Carey Robert Director Dec 18 '23 Buy 1.64 1,200,000 1,962,000 2,374,454 Dec 19 05:13 PM Lisi Steven A. CEO and Chairman of the Board Dec 18 '23 Buy 1.63 77,775 126,797 1,536,471 Dec 19 05:15 PM Gaul Michael A. Chief Operating Officer Nov 16 '23 Buy 1.77 10,000 17,700 88,150 Nov 17 04:15 PM Carey Robert Director Aug 28 '23 Buy 2.69 250,000 673,750 1,225,160 Aug 29 04:10 PM Carey Robert Director Aug 21 '23 Buy 2.76 75,050 207,453 975,160 Aug 22 04:10 PM Carey Robert Director Aug 18 '23 Buy 2.64 13,614 35,940 900,110 Aug 22 04:10 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
